- Home
- TPIC vs PRLD Comparison
TPIC vs PRLD Comparison
Compare TPIC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- PRLD
- Stock Information
- Founded
- TPIC 1968
- PRLD 2016
- Country
- TPIC United States
- PRLD United States
- Employees
- TPIC N/A
- PRLD N/A
- Industry
- TPIC Industrial Machinery/Components
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- TPIC Industrials
- PRLD Health Care
- Exchange
- TPIC Nasdaq
- PRLD Nasdaq
- Market Cap
- TPIC 65.6M
- PRLD 73.7M
- IPO Year
- TPIC 2016
- PRLD 2020
- Fundamental
- Price
- TPIC $0.79
- PRLD $0.77
- Analyst Decision
- TPIC Hold
- PRLD Strong Buy
- Analyst Count
- TPIC 6
- PRLD 2
- Target Price
- TPIC $1.86
- PRLD $4.50
- AVG Volume (30 Days)
- TPIC 840.9K
- PRLD 254.5K
- Earning Date
- TPIC 05-01-2025
- PRLD 03-10-2025
- Dividend Yield
- TPIC N/A
- PRLD N/A
- EPS Growth
- TPIC N/A
- PRLD N/A
- EPS
- TPIC N/A
- PRLD N/A
- Revenue
- TPIC $1,331,131,000.00
- PRLD $7,000,000.00
- Revenue This Year
- TPIC $8.93
- PRLD N/A
- Revenue Next Year
- TPIC $9.59
- PRLD N/A
- P/E Ratio
- TPIC N/A
- PRLD N/A
- Revenue Growth
- TPIC N/A
- PRLD N/A
- 52 Week Low
- TPIC $0.73
- PRLD $0.63
- 52 Week High
- TPIC $5.75
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- TPIC 37.29
- PRLD 50.06
- Support Level
- TPIC $0.73
- PRLD $0.71
- Resistance Level
- TPIC $0.87
- PRLD $0.76
- Average True Range (ATR)
- TPIC 0.11
- PRLD 0.07
- MACD
- TPIC -0.00
- PRLD 0.02
- Stochastic Oscillator
- TPIC 12.54
- PRLD 58.46
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.